Fatal intoxication with PMMA – a novel designer analogue of amphetamine

1. Ayres TC, Bond JW. A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill) health. Legal highs or illegal highs? BMJ Open 2012;2:e000977.10.1136/bmjopen-2012-000977Search in Google Scholar

2. European Monitoring Centre for Drugs and Drugs Addiction. Annual report 2010: the state of the drugs problem in Europe. Luxembourg: Publications Office of the European Union; 2010. http://www.emcdda.europa.eu/publications/annual-report/2010 (20.05.2019).Search in Google Scholar

3. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephe-drone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 2011;214(3):593-602.10.1007/s00213-010-2070-xSearch in Google Scholar

4. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013;168(2):458-70.10.1111/j.1476-5381.2012.02145.xSearch in Google Scholar

5. Blanckaert P, van Amsterdam J, Brunt T, van den Berg J, Van Durme F, Maudens K, et al. 4-Methyl-amphetamine: a health threat for recreational amphetamine users. J Psychopharmacol 2013;27(9):817-22.10.1177/0269881113487950Search in Google Scholar

6. Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties and cannabimimetics and amphetamine-like stimulants. Front Neurosci 2016;10:153.10.3389/fnins.2016.00153Search in Google Scholar

7. Miller KJ, Anderholm DC, Ames MM. Metabolic activation of serotonergic neurotoxin para-chloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations. Biochem Pharmacol 1986;35(10):1737-42.10.1016/0006-2952(86)90332-1Search in Google Scholar

8. Wojcieszak J. Związki psychostymulujące. In: Zawilska JB, Andrzejczak D, Wojcieszak W. „Dopalacze” i leki OTC – nowi gracze na scenie związków psychoaktywnych. Łódź: Uniwersytet Medyczny w Łodzi; 2016. p. 45-71.Search in Google Scholar

9. Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu narkomanii. Dz. U. Nr 179, poz. 1485.Search in Google Scholar

10. Antonowicz JL, Metzger AK, Ramanujam SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011;33(6):640.e5-6.10.1016/j.genhosppsych.2011.04.01021749840Search in Google Scholar

11. Fullajtar M, Ferencz C. Designer drug induced psychosis. Neuropsychopharmacol Hung 2012;14(2):137-40.Search in Google Scholar

12. Mugele J, Nañagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med 2012;60(1):100-2.10.1016/j.annemergmed.2011.11.03322237165Search in Google Scholar

13. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3(7-8):439-53.10.1002/dta.31321755607Search in Google Scholar

14. Zawilska JB, Słomiak K, Wasiak M, Woźniak P, Massalski M, Krupa E, et. al. β-cathinones derivatives – a new generation of dangerous psychostimulant “designer drug”. Prz Lek 2013;70(6):386-91.Search in Google Scholar

15. Vevelstad M, Øiestad EL, Bremer S, Bogen IL, Zackrisson AL, Arnestad M. Is toxicity of PMMA (paramethoxymethamphetamine) associated with cytochrome P450 pharmacogenetics? Forensic Sci Int 2016;261:137-47.Search in Google Scholar